Loading news...
4:05pm: In the red US stocks remained under pressure on Friday afternoon as investors reacted to new data indicating slowing economic growth amid the...
4:15pm: Tech stocks take hit Wall Street plunged Thursday as Middle East tensions sent oil soaring past $100 a barrel, stoking fears of a wider conflict and...
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that an abstract from its SUNRISE-PD study evaluating its lead candidate bezisterim (NE3107) for Parkinson's disease has been accepted for presentation at the AD/PD 2026 Advances in Science & Therapy annual meeting. The conference is scheduled to take place March 17 to 21, 2026, in Copenhagen, Denmark.
UiPath Inc (NYSE:PATH) reported stronger-than-expected fourth-quarter results driven by healthy subscription growth and rising profitability. The automation...
BioVie Inc. (BIVI) Discusses Clinical Progress of Bezisterim Targeting Inflammation in Parkinson's, Alzheimer's, and Long COVID Transcript
Roku Inc (NASDAQ:ROKU) shares climbed almost 5% following the company’s release of fourth quarter 2025 results, which exceeded Wall Street expectations and...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Thursday that two abstracts highlighting research on its lead drug candidate bezisterim (NE3107) have been accepted for presentation at the 2026 American College of Psychiatrists annual meeting in Bonita Springs, Florida. The abstracts, which focus on bezisterim's potential in Alzheimer's disease and Long COVID, will be presented as posters on February 18.
10am: Dow opens higher, Nasdaq dips US stocks have made another uneven start. The Dow Jones and S&P 500 have opened 0.4% and 0.2% higher, but the Nasdaq...
In biotech, the most compelling investment stories often emerge where medical need, scientific differentiation, and timing intersect. BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW), a clinical-stage biopharmaceutical company with a market capitalization still measured in the tens of millions, is attempting exactly that by targeting what it believes is a root driver of neurodegeneration rather than merely treating symptoms.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed enrolment in a closely watched mid-stage trial testing whether its experimental drug bezisterim can slow the progression of early Parkinson's disease, putting the group on track for key data later this year. The Phase 2 study, known as SUNRISE-PD, has enrolled 60 patients who were diagnosed within the past four years and have not yet been treated with standard levodopa therapy.
BioVie Inc. (NASDAQ: BIVI - Get Free Report) dropped 4.7% during trading on Wednesday. The company traded as low as $1.21 and last traded at $1.21. Approximately 79,581 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 122,030 shares. The stock had previously closed at $1.27. Analysts Set
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioVie Inc. (NASDAQ: BIVI) breached their fiduciary duties to shareholders.
Indus Gas (LSE:INDI) shares lost more than half their value after announcing plans to cancel its listing on AIM. The company, in a statement, cited limited...
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do talked with Proactive about the company's recent developments in its two lead drug candidates: Bezisterim and BIV201. Bezisterim, which blocks TNF alpha to reduce inflammation, is being trialed in Parkinson's disease, long COVID, and Alzheimer's.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do talked with Proactive about the company’s recent developments in its two lead drug candidates:...
BioVie (BIVI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease Transcript
CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on December 9, 2025, at 4:15 p.m. ET.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioVie Inc. (NASDAQ: BIVI) breached their fiduciary duties to shareholders. If you currently own BioVie stock and acquired shares on or before December 7, 2022, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more abou.